DiaMedica Inc. is a clinical-stage biopharmaceutical company, which focuses on recombinant proteins and monoclonal antibodies. The Company focuses on the discovery and development of treatments for stroke and other vascular diseases. It operates through segment, which is discovery and development of recombinant proteins and monoclonal antibody technology applications to treat large unmet diseases, including acute vascular disease of the brain, kidneys and heart. Its product, DM199, is a recombinant human tissue kallikrein-1 protein engineered to duplicate the actions of the naturally occurring human kallikrein-1 protein produced in the pancreas, kidneys and salivary glands of humans as a response to oxidative stress challenges. Its drug, Recombinant tissue plasminogen activator, is intended for the treatment of acute ischemic stroke (AIS). DM199 has also completed a Phase I/II clinical trials in Type 2 diabetic patients.